343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA
Amendment to Executive Severance Plan Approved by Vistagen Board
Investor Presentation
Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
2026 Annual Meeting Results: Directors Elected and Executive Compensation App...
Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
FY 2025
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence